Drug Trial Radar · NCT04509674
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,522
Actual
Start
Dec 16, 2020
Primary completion
Nov 5, 2023
Study completion Nov 5, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease. People who are in hospital may join the study soon after being treated for their heart attack. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. All participants continue their standard treatment. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. Empagliflozin is a medicine that helps people with type 2 diabetes to lower their blood sugar. Researchers think that empagliflozin might also help people after heart attack who are at risk for heart failure, whether or not they have diabetes. Participants are in the study for about 1 to 2 years. During this time, there are about 4 visits inperson, 2 visits are done either by phone or by use of an mobile application. Results between the empagliflozin and placebo groups are compared. The doctors also regularly check the general health of the participants.
Conditions
- Myocardial Infarction
Interventions
EmpagliflozinDrug
Empagliflozin
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Time to First Heart Failure Hospitalisation or All-cause MortalityTime frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Locations
439 sites in 22 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular LLC
Alexander City, Alabama
Grandview Medical Center
Birmingham, Alabama
Heart Center Research, LLC
Huntsville, Alabama
Mercy Gilbert Medical Center
Gilbert, Arizona
Arkansas Cardiology, PA
Little Rock, Arkansas
Comprehensive Cardiovascular Medical Group
Bakersfield, California
Valley Clinical Trials, Inc.
Covina, California
Cardiovascular Innovation and Research Center
Long Beach, California
University of California Los Angeles
Los Angeles, California
InvivoCure
Mission Hills, California
Valley Clinical Trials, Inc.
Northridge, California
Valley Clinical Trials, Inc.
Pasadena, California
Kaiser Permanente
San Diego, California
San Diego Cardiac Center
San Diego, California
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Interventional Cardiology Medical Group
West Hills, California
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
Clearwater Cardiovascular Consultants
Clearwater, Florida
Integrative Research Associates
Fort Lauderdale, Florida
University of Florida Health Jacksonville
Jacksonville, Florida
Cardiology Partners Clinical Research Institute
Palm Beach Gardens, Florida
Charlotte Heart Group Research Center
Port Charlotte, Florida
Grady Memorial Hospital
Atlanta, Georgia
Cardiovascular Consultants of South Georgia, LLC
Thomasville, Georgia
Atlanta Heart Specialists, LLC
Tucker, Georgia
Advanced Heart Care, LLC, Medicoricum, LLC
Fairview Heights, Illinois
Midwest Cardiovascular Research and Education Foundation
Elkhart, Indiana
Cardiovascular Research of Northwest Indiana, LLC
Munster, Indiana
Reid Physician Associates
Richmond, Indiana
Midwest Heart and Vascular Specialists
Overland Park, Kansas
University of Kentucky Medical Center
Lexington, Kentucky
University of Louisville
Louisville, Kentucky
Eastern Maine Medical Center
Bangor, Maine
Cardiovascular Specialists of Central Maryland
Columbia, Maryland
Shady Grove Adventist Hospital
Rockville, Maryland
Healthy Heart Cardiology
Grand Rapids, Michigan
Western Michigan University
Kalamazoo, Michigan
Mid Michigan Medical Center
Midland, Michigan
Michigan Heart, PC
Ypsilanti, Michigan
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
Showing 40 of 439 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.